- Page 1 and 2:
The Expert Committee on Specificati
- Page 3 and 4:
W H O T e c h n i c a l R e p o r t
- Page 5 and 6:
Contents WHO Expert Committee on Sp
- Page 7 and 8:
12.4 Proposal for a procedure on sa
- Page 9 and 10:
WHO Expert Committee on Specificati
- Page 11 and 12:
WHO Expert Committee on Specificati
- Page 13:
WHO Expert Committee on Specificati
- Page 16 and 17:
2. General policy 2.1 Cross-cutting
- Page 18 and 19:
WHO Expert Committee on Specificati
- Page 20 and 21:
WHO Expert Committee on Specificati
- Page 22 and 23:
WHO Expert Committee on Specificati
- Page 24 and 25:
WHO Expert Committee on Specificati
- Page 26 and 27:
WHO Expert Committee on Specificati
- Page 28 and 29:
4. Quality control - International
- Page 30 and 31:
WHO Expert Committee on Specificati
- Page 32 and 33:
WHO Expert Committee on Specificati
- Page 34 and 35:
WHO Expert Committee on Specificati
- Page 36 and 37:
7. Quality assurance - new approach
- Page 38 and 39:
WHO Expert Committee on Specificati
- Page 40 and 41:
WHO Expert Committee on Specificati
- Page 42 and 43:
9. Prequalification of priority ess
- Page 44 and 45:
11. Prequalification of quality con
- Page 46 and 47:
WHO Expert Committee on Specificati
- Page 48 and 49:
WHO Expert Committee on Specificati
- Page 50 and 51:
14. Miscellaneous 14.1 Quality assu
- Page 52 and 53:
WHO Expert Committee on Specificati
- Page 54 and 55:
WHO Expert Committee on Specificati
- Page 56 and 57:
WHO Expert Committee on Specificati
- Page 58 and 59:
WHO Technical Report Series, No. 98
- Page 60 and 61:
WHO Expert Committee on Specificati
- Page 62 and 63:
WHO Expert Committee on Specificati
- Page 64 and 65:
WHO Expert Committee on Specificati
- Page 66 and 67:
WHO Expert Committee on Specificati
- Page 68 and 69:
WHO Expert Committee on Specificati
- Page 70 and 71:
WHO Expert Committee on Specificati
- Page 73 and 74:
Annex 1 Release procedure for Inter
- Page 75 and 76:
Annex 2 WHO guidelines on quality r
- Page 77 and 78:
Annex 2 While the choice of the too
- Page 79 and 80:
Annex 2 ■■ The level of effort,
- Page 81 and 82:
Annex 2 within companies and, where
- Page 83 and 84:
Annex 2 risk analysis The estimatio
- Page 85 and 86:
Annex 2 3.3 Knowledge of the produc
- Page 87 and 88:
Annex 2 During risk control activit
- Page 89 and 90:
Annex 2 diagrams and appropriate re
- Page 91 and 92:
Annex 2 Similarly, contract staff m
- Page 93 and 94:
Annex 2 4.5 QRM application during
- Page 95 and 96:
Annex 2 Among others, QRM methodolo
- Page 97 and 98:
Annex 2 ■■ ■■ ■■ ■■
- Page 99 and 100:
Annex 2 All documentation related t
- Page 101 and 102:
Annex 2 6. Risk management tools A
- Page 103 and 104:
Annex 2 This table is a very basic
- Page 105 and 106:
Annex 2 Table 3 continued Risk mana
- Page 107 and 108:
Annex 3 WHO guidelines on variation
- Page 109 and 110:
Annex 3 3.2. P.5 Control of FPP 142
- Page 111 and 112:
Annex 3 to implementation, assessme
- Page 113 and 114:
Annex 3 WHO/PQP should be notified
- Page 115 and 116:
Annex 3 2.1.2 Minor variation (Vmin
- Page 117 and 118:
Annex 3 active pharmaceutical ingre
- Page 119 and 120:
Annex 3 Table continued Description
- Page 121 and 122:
Annex 3 Table continued Documentati
- Page 123 and 124:
Annex 3 Table continued Description
- Page 125 and 126:
Annex 3 Table continued Documentati
- Page 127 and 128:
Annex 3 Table continued Description
- Page 129 and 130:
Annex 3 Table continued Description
- Page 131 and 132:
Annex 3 Table continued Description
- Page 133 and 134:
Annex 3 Table continued Description
- Page 135 and 136:
Annex 3 Table continued Documentati
- Page 137 and 138:
Annex 3 Table continued Conditions
- Page 139 and 140:
Annex 3 Table continued Description
- Page 141 and 142: Annex 3 Table continued Conditions
- Page 143 and 144: Annex 3 Table continued Conditions
- Page 145 and 146: Annex 3 Table continued Description
- Page 147 and 148: Annex 3 Table continued Conditions
- Page 149 and 150: Annex 3 Table continued Description
- Page 151 and 152: Annex 3 Table continued Conditions
- Page 153 and 154: Annex 3 Table continued Documentati
- Page 155 and 156: Annex 3 Table continued Description
- Page 157 and 158: Annex 3 Table continued Description
- Page 159 and 160: Annex 3 Table continued Conditions
- Page 161 and 162: Annex 3 Table continued Documentati
- Page 163 and 164: Annex 3 Table continued Documentati
- Page 165 and 166: Annex 3 3.2. P.8 Stability Descript
- Page 167 and 168: Annex 3 Appendix 1 Examples of chan
- Page 169 and 170: Annex 4 Collaborative procedure bet
- Page 171 and 172: Annex 4 ■■ ■■ ■■ associ
- Page 173 and 174: Annex 4 3.2 WHO/PQP and participati
- Page 175 and 176: Annex 4 3.7 The decision whether or
- Page 177 and 178: Annex 4 that a WHO-prequalified pro
- Page 179 and 180: Annex 4 Figure 1 Flowchart showing
- Page 181 and 182: Annex 4 Figure 1 continued Post-reg
- Page 183 and 184: Annex 4 5.5 WHO/PQP removes a produ
- Page 185 and 186: Annex 4 such Product that it will a
- Page 187 and 188: Annex 4 Timelines In respect of eac
- Page 189 and 190: Annex 4 Title in NMRA: E-mail: Phon
- Page 191: Annex 4 secret access code and from
- Page 195 and 196: Annex 4 Appendix 3 Expression of in
- Page 197 and 198: Annex 4 -- information and document
- Page 199 and 200: Annex 4 Date of prequalification (d
- Page 201 and 202: Annex 4 Appendix 4 Report on post-r